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The effectiveness of FMD vaccines is influenced by multiple 
factors such as route of vaccination, dose, similarity to 
circulating virus and adjuvant. Antigen integrity is also 
imperative for vaccine efficacy; FMD vaccines that are 
comprised of dissociated viral particles do not elicit adequate 
levels of protective neutralising antibodies. This problem is 
exacerbated by the fact FMDV capsids (146S particles) 
readily dissociate at mild acidic conditions and at room 
temperature into their constituent subunits (12S particles). In 
addition, chemical inactivation further decreases the stability 
of the FMDV capsid (Doel and Baccarini, 1981).  
 
A research team headed by Bryan Charleston at The 
Pirbright Institute in the UK has recently focused on (i) the 
development of alternative FMDV vaccines based on virus-
like particles (VLPs), and (ii) the generation and 
characterization of more stable infectious virions and VLPs. 
To quantify the antigen content and integrity of these new 
vaccine candidates two different assays have been 
developed. The first, termed the thermofluor assay, is a 
qPCR-based technique that monitors viral genome release as 
an indicator of capsid disassembly using a dye sensitive to 
the presence of nucleic acid during a slow increase in 
temperature. The second assay is ELISA-based and uses 
llama single-domain antibodies (VHHs) that are specific for 
intact viral capsids.  Michiel Harmsen and Aldo Dekker at  
the Central Veterinary Institute Wageningen UR, The 
Netherlands (CVI), have developed the selection of such 
146s specific VHHs using phage display libraries derived 
from llamas immunized against FMDV. Both assays are user
-friendly and can be quickly performed with minimal 
training using standard laboratory equipment. In 
combination, the techniques complement each other and 
have the potential to be applied for quality control of FMDV 
vaccines, both during and after the production process, as 
well as for the characterisation of optimal vaccine storage 
conditions.  
 
At the 2014 EuFMD meeting in Croatia, the use of both 
techniques as diagnostic tools for FMDV capsid stability was 
presented, generating a lot of interest amongst the FMDV 
community. This has led to a successful application for 
EuFMD-FAR funding. The collaborative project combines 
the technical expertise of Julian Seago and Eva Perez at TPI 
in performing the assays with established methodologies at 
CVI in the production of VHHs. The project will develop 
and assess the assays on FMD vaccine strains currently 
being produced in East Africa by vaccine companies, with 
the intention of transferring the technologies for their future 
application; this will be mediated through Nick Lyons at TPI 
and Vish Nene at the International Livestock Research 
Institute (ILRI) in Kenya. 
 
Figure 1: Schematic representation of a FMDV virion 
(146S) dissociating into its constituent pentameric subunits 
(12S) and RNA genome. Positions of the  three structural 
proteins (VP1-3) on  the external surface of the capsid are 
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FMD is not simply a contagious disease of cloven-hooved 
livestock, but can be considered as a complex of diseases 
caused by numerous genetic and antigenic variants with 
different geographic distributions and epidemiologies, 
belonging to the seven serotypes, A, O, C, Asia-1, Southern 
African Territories (SAT) type 1, SAT2 and SAT3 . In 
Africa, the epidemiology of FMD is influenced by two 
different patterns, i.e. a cycle involving wildlife, in particular 
the African buffalo (Syncerus caffer), and an independent 
cycle maintained within livestock. Another unique feature of 
FMD epidemiology in Africa is the presence of the three 
SAT serotypes, which are maintained within the African 
buffalo populations. Therefore, the presence of large 
numbers of African buffalo provides a potential source of 
sporadic infection to livestock and other wildlife species. 
